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PURPOSE: Surgical lung biopsy has been studied in distinct populations, mostly going beyond clinical issues to impinge upon
routine histopathological diagnostic information in diffuse infiltrates; however, detailed tissue analyses have rarely been performed.
The present study was designed to investigate the prognostic contribution provided by detailed tissue analysis in diffuse infiltrates.
METHODS: Medical records and surgical lung biopsies from the period of 1982 to 2003 of 63 patients older than 18 years with
diffuse infiltrates were retrospectively examined. Lung parenchyma was histologically divided into 4 anatomical compartments:
interstitium, airways, vessels, and alveolar spaces. Histological changes throughout these anatomical compartments were then
evaluated according to their acute or chronic evolutional character. A semiquantitative scoring system was applied to histologic
findings to evaluate the intensity and extent of the pathological process. We applied logistic regression to predict the risk of death
associated with acute and chronic histological changes and to estimate the odds ratios for each of the independent variables in the
model.
RESULTS: Impact on survival was found for male gender (P = 0.03), presence of diffuse alveolar damage (P = 0.001), and
chronic histological changes (P = 0.0004) on biopsy. Thus, being male was associated with a slightly lower risk (O.R. = 0.18;
P=0.03) of dying than being female. Death risk was increased 17 times in the presence of acute histological changes such as
diffuse alveolar damage and 2.5 times in the presence of chronic histological changes.
CONCLUSION: Detailed analysis of histological specimens can provide more than a nosological diagnosis: this approach can
provide valuable information concerning prognosis.
KEYWORDS: Surgical lung biopsy. Diffuse pulmonary infiltrate. Histopathological score. Diffuse alveolar damage. Prognosis.
INTRODUCTION
Diffuse pulmonary disease of uncertain etiology repre-
sents a diagnostic and therapeutic challenge in the general
population. Most of the causes of pulmonary infiltrates can
be diagnosed by noninvasive or minimally invasive means,
such as transbronchial or transthoracic needle biopsies.
However, when these efforts fail to provide a diagnosis or
when a patient does not respond to appropriate therapy, a
surgical lung biopsy may be required to assist in treatment
efforts. This biopsy produces a histologic diagnosis in al-
most every case, but considerable controversy exists regard-
ing whether the information provided justifies its routine
use. Thus, similarly to the approach used from previously
reported tumor recurrence studies1–5 and aiming for the ef-
fectiveness of treatment, there is great interest in identify-
ing, as soon as possible, morphological parameters of sur-
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gical lung biopsies associated with the shortening of the
patient’s life.
Because semiquantitative approaches have been thought
to be important in evaluating the intensity and extent of
pathologic processes,6–9 a scoring system has been consid-
ered to be potentially useful with surgical lung biopsies
specimen markers.10,11 Several parenchymal alterations re-
lated to necrosis, degeneration, hyperplasia, neoplasia, in-
flammation/remodeling (fibrin and hyaline membranes
deposition, polymorphonuclear and mononuclear cell in-
filtration, granulation tissue, granuloma, fibrocellular pro-
liferation), and circulatory changes (edema, hemorrhage,
congestion, thrombosis) have shown promise as useful
markers.
Scoring systems have also been found to be significantly
associated with survival,8,12 but there has been uncertainty
about how best to design a scoring system. Hence, this
project was undertaken to validate the importance of a scor-
ing system and to explore the semiquantitative relationship
between score and outcome; we also explored the relation-




We examined the medical records of all patients who
underwent surgical lung biopsy at our institution from 1982
to 2003 for age, sex, total hospitalization time, days from
admission to the biopsy procedure, outcome, main clini-
cal diagnosis, underlying disease, respiratory failure proven
through clinical and or gasometric data (respiratory rate
over 28 breaths per minute and/or PaO2 < 60 mm Hg and/
or SpO2 < 90%, while breathing room air). From this group
were selected those patients older than 18 years showing
diffuse infiltrates on chest roentgenogram and whose hos-
pitalization was not exclusively motivated by the biopsy
procedure.
Over the period examined, 1657 surgical lung biopsies
were performed at our institution; 63 patients (3.8%) met
our study criteria. Thirty-two patients (51%) were men and
31 (49%) were women, with a mean age of 49 years (range,
18 to 92 years). Arterial blood samples for gas analysis
taken during inspiration of room air in the 24 hours pre-
ceding SLB were obtained for 51 patients (81%), and 41
of them showed signs of acute respiratory failure. Table 1
lists the preexisting medical conditions in the study popu-
lation. Thirty-three patients (52%) were
immunocompromised, and 48 (76%) had at least 1 under-
lying disease. The mean time from admission to SLB was
18 days (range, 0 to 61). The mean interval from SLB to
hospital discharge or death was 18 days (range, 1 to 143),
and the mean total hospitalization time was 39 days (range,
4 to 184). The overall death rate was 49%, and death rate
for immunocompromised patients and for patients present-
ing respiratory failure or underlying diseases was 61%.
Death occurred in 69% of patients presenting diffuse al-
veolar damage. Other details about the patients are sum-
marized in Table 1.
Pathology review of surgical lung biopsy specimens
Samples were uniform and obtained generally in 2 dif-
ferent compromised regions; the entire sample was submit-
ted to histological examination, generally on 2 different
slides. The specimens were fixed in 10% phosphate-buff-
ered formaldehyde solution and embedded in paraffin. Se-
rial sections were cut (5 mm), deparaffinized, and processed
according to routine tissue processing. Staining with
hematoxylin and eosin was done for histological examina-
tion in all cases. In cases exhibiting proteinaceous intra-
alveolar exudates, granulomas, or microabscesses, the fol-
lowing stains were used: silver stains and PAS for
Pneumocystis and fungi, Ziehl-Neelsen for mycobacterium,
and Gram stains for bacteria, respectively.
The biopsies were considered representative when the
histological sections comprised at least 1 bronchovascular
axis in continuity with septal interstitium, alveolar spaces,
and peripheral interstitium. The lung parenchyma was then
histologically divided into 4 anatomical compartments of
reference: a) interstitium (septal, peripheral, and axial); b)
airways (terminal and respiratory bronchioles); c) vessels
(arteries, veins, and lymphatics); and d) alveolar spaces (in-
cluding alveolar ducts) (Figure 1).
Histological changes throughout the 4 anatomical com-
partments were then evaluated for temporal evolution into
2 groups as follows: 1) acute (necrosis, degeneration,
edema, hemorrhage, congestion, thrombosis, fibrin depo-
sition, hyaline membranes, and polymorphonuclear cells),
and 2) chronic (hyperplasia, neoplasia, mononuclear cells,
granulation tissue, granuloma, and fibrocellular prolifera-
tion) (Figures 2A to 2I and 3A to 3F).
Semiquantitative assessment of histological
compartments and histological changes
The severity of the acute and chronic histological
changes in terms of the extent, intensity, and distribution
were heterogeneous along the anatomic compartments.
Therefore, the severity of these various acute and chronic
histological changes was rated semiquantitatively accord-
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Table 1 - Epidemiological data of the 63 patients studied
Case Sex Age Total Hospitalization Underlying disease Presence of immunosuppression Outcome
Time (days) factor
1 m 56 20 No No Dead
2 m 48 32 No No Dead
3 m 76 60 Renal and heart failure No Survived
4 f 19 47 BMT (aplastic anemia) Yes Dead
5 m 67 44 No No Survived
6 m 55 17 Rheumatologic disease NOS No Dead
7 f 52 27 Heart failure No Survived
8 m 48 55 Crohn’s disease+ renal failure No Dead
9 m 66 42 Rheumatoid arthritis No Dead
10 f 37 44 SLE No Dead
11 m 34 16 AIDS Yes Dead
12 m 45 18 CML Yes Dead
13 m 52 20 No No Survived
14 f 21 38 Non-Hodgkin’s lymphoma Yes Survived
15 f 30 37 No No Survived
16 f 63 9 Carcinomatosis Yes Dead
17 m 37 48 No No Dead
18 f 51 22 Gastroesophageal reflux No Survived
19 m 52 38 Liver cirrhosis No Survived
20 f 46 26 Adenocarcinoma NOS No Dead
21 f 34 4 CML Yes Dead
22 f 49 19 Carcinomatosis Yes Survived
23 m 23 21 Burns No Dead
24 m 58 13 Adenocarcinoma NOS Yes Dead
25 m 77 45 COPD Yes Dead
26 m 36 20 BMT Yes Dead
27 m 78 17 No Yes Survived
28 f 54 9 SLE No Dead
29 f 51 184 Wegener’s granumatosis No Dead
30 m 57 33 Ischemic myocardiopathy No Dead
31 f 21 42 SLE No Survived
32 f 74 16 Congestive myocardiopathy No Dead
33 m 55 91 Congestive myocardiopathy No Dead
34 m 65 69 Sarcoidosis No Dead
35 f 46 15 Wegener’s granumatosis No Survived
36 f 52 76 No Yes Survived
37 f 92 24 Ischemic myocardiopathy No Survived
38 f 26 27 BMT (CML) Yes Dead
39 f 53 98 Rheumatoid arthritis No Dead
40 m 70 47 Non-Hodgkin’s lymphoma Yes Dead
41 f 30 65 Colitis NOS No Survived
42 f 82 22 Neoplasia NOS Yes Survived
43 f 50 91 SLE Yes Survived
44 m 57 38 Gastroesophageal reflux+DM 2 No Survived
45 m 65 37 Ischemic myocardiopathy+DM 2 No Dead
46 m 47 37 ALL Yes Dead
47 m 32 16 ALL Yes Dead
48 f 68 37 Hypertension No Survived
49 m 53 26 Heart transplantation Yes Dead
50 m 22 89 ALL Yes Survived
51 m 18 7 BMT (ALL) Yes Survived
52 f 76 36 Ischemic myocardiopathy No Dead
53 f 55 17 Carcinomatosis Yes Dead
54 f 25 47 No No Survived
55 f 38 42 No No Dead
56 m 37 84 CML Yes Dead
57 f 36 10 Ischemic myocardiopathy No Survived
58 f 36 14 Carcinomatosis Yes Survived
59 m 73 34 No No Survived
60 f 52 36 No No Survived
61 m 31 49 SLE No Dead
62 m 28 48 Aplastic anemia Yes Dead
63 f 73 37 No No Survived
AIDS: acquired immunodeficiency syndrome; ALL: acute lymphocytic leukemia; BMT: bone marrow transplantation; CML: chronic myelocytic
leukemia; CPOD: chronic obstructive lung disease; DM: diabetes mellitus; NOS: no other specification; SLE: systemic lupus erythematous.
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The sum of the scores for acute and chronic changes,
respectively, represented continuous variables that we des-
ignated as acute and chronic indices.
Statistical Analysis
Logistic regression analysis was used to attain the best
separation of survivors and nonsurvivors, discriminating
between the two categories of patients according to clini-
cal and histological variables. Evaluation of the predictive
ability was determined by the percentage of patients cor-
rectly placed into the proper categories by the classifica-
tion rules developed. In logistic regression, the probability
of an event occurring is directly estimated. For more than
1 dependent variable, the model can be written:
Prob (event) = ez / 1 + ez
where Z is the linear combination of β0 (constant) and β1
to β7, the estimated coefficients of the independent vari-
ables (X1 to X7), and e is the base of the natural logarithms,
(2.718, approximately), as shown below:
Z = β0 + β1X1 + β2 X2 …β7 X7
We considered results with P values less than 5% to be
statistically significant. All analysis was done with SPSS
for Windows 10.0 statistical software.
RESULTS
The total mean score for acute histological changes was
2.11 (range, 0.02 to 0.56), and for chronic histological
changes it was 4.09 (range, 0.14 to 0.76) (Table 2). The
acute or chronic compromise of axial interstitium and air-
ways characterized respectively acute and chronic bronchi-
Figure 1 - (HE, 25X):  Normal lung histology showing the 4 compartments
studied: interstitium, alveolar spaces, airways and vessels. “PI”: peripheral
interstitium; “SI”: septal interstitium; “AI”: axial interstitium; “*”: alveolar
spaces; “TB”: terminal bronchioles; “A”: pre-acinar arterioles
Figure 2 - A (HE, 100X): parenchymal necrosis; B (HE, 200X): alveolar
edema; C (HE, 100X): peripheral interstitium edema; D (HE, 200X): alveolar
hemorrhage; E (HE, 200X): microvascular congestion; F (HE, 200X): acute
vascular thrombosis; G (HE, 200X): alveolar fibrin deposition; H (HE,
200X): hialine membranes; I (HE, 200X): neutrophilic filling of alveolar
spaces
Figure 3 - A (HE, 200X): pneumocytes hyperplasia; B (HE, 200X):
neoplastic parenchymal infiltration; C (HE, 200X): mononuclear cell
interstitial infiltrate; D (HE, 200X): granulation tissue filling alveolar spaces;
E (HE, 200X): granuloma; F (HE, 200X): fibrosis (fibrocellular proliferation)
ing to the amount and severity of disease by the following
histological score:
0: absence of histological changes;
1: parenchymal alterations in 1 to 25% of the tissue ex-
amined;
2: parenchymal alterations in 26 to 50% of the tissue ex-
amined;
3: parenchymal alterations in 51 to 75% of the tissue ex-
amined;
4: parenchymal alterations in 76% to 100% of the tissue
examined.
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olitis (Figure 4A). Similarly, the acute or chronic compro-
mise of septal and peripheral interstitium, alveolar spaces,
and vessels comprised the histologic pattern of chronic in-
terstitial pneumonia (Figure 4B), diffuse alveolar damage
(Figure 4C), and vasculitis (Figure 4D), respectively (Ta-
ble 2). Table 3 shows the predictive ability for survival of
the clinical and histological variables evaluated using the
logistic regression model. Statistically significant impact
on survival was found for male gender (P = 0.03), diffuse
alveolar damage (P = 0.001), and chronic histological
changes (P = 0.0004). Thus, being male was associated
with a lower risk (O.R. = 0.18; P=0.03) of dying than be-
ing female. Presence of acute histological changes, such
as diffuse alveolar damage at biopsy, increased the risk of
death 17.5 times, whereas the presence of chronic histo-
logical changes increased risk of death related 2.5 times.
Although not statistically significant, patients with immu-
nosuppression, arterial hypertension, and chronic cardiac
Figure 4 - Prototypical histopathological changes: A (HE, 200X): chronic
bronchiolitis with squamous metaplasia; B (HE, 200X): non-specific
interstitial pneumonia (cellular pattern); C (HE, 200X): diffuse alveolar
damage;  D (HE, 200X): chronic vasculitis
Table 2 - Mean, maximum, and minimum values of the acute and chronic histological score obtained by semiquantitative
assessment
Histological compartments Temporal evolution N Score Histological changes
Mean Minimum Maximum
Septal interstitium acute 63 0.19 0 1.25 Diffuse alveolar damage
chronic 63 0.55 0 1.38
Alveolar spaces acute 63 0.56 0 1.20
chronic 63 0.36 0 1.13 Chronic interstitial pneumonia
Peripheral interstitium acute 63 0.31 0 1.67
chronic 63 0.76 0 2.50
Axial interstitium acute 63 0.08 0 0.60 Acute bronchiolitis
chronic 63 0.45 0 1.75
Terminal bronchioles acute 63 0.38 0 1.00
chronic 63 0.14 0 0.67 Chronic bronchiolitis
Respiratory bronchioles acute 63 0.37 0 1.00
chronic 63 0.26 0 1.00
Pre-acinar arterioles acute 63 0.12 0 0.43 Acute vasculitis
chronic 63 0.44 0 1.25
Post-acinar arterioles acute 63 0.08 0 0.67
chronic 63 0.40 0 1.33 Chronic vasculitis
Veins and lymphatics acute 63 0.02 0 0.50
chronic 63 0.73 0 2.25
Table 3 - Evaluation of the risk of death using the scoring system on surgical lung biopsies by the multiple logistic
regression model (chi-square = 32.9; P < 0.001)
Variable β SE Wald P Exp(B) 95% CI for Exp(B)
Lower Upper
Gender -1.68 0.78 4.61 0.031 0.18 0.039 0.86
Diffuse alveolar damage 2.83 0.86 10.78 0.001 17.05 3.13 92.74
Chronic histological score 0.86 0.25 11.41 0.000 2.36 1.43 3.89
Systemic arterial hypertension 2.34 1.27 3.35 0.067 10.39 0.84 127.32
Cardiac chronic failure 0.41 2.37 0.03 0.862 1.50 0.01 159.53
Diabetes mellitus -1.24 1.86 0.44 0.506 0.28 0.01 11.26
Immunosuppression 0.88 0.73 1.48 0.22 2.43 0.58 10.19
Constant 0.82 36.79 0.00 0.982
β: coefficient of model; SE: Standard error; Wald: Wald statistics; P: probability of the null hypothesis; Exp (B): odds ratio; CI: confidence interval.
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failure presented an apparently greater risk of death. When
this model was evaluated on the original data used for its
development, 26 of 32 (81.3%) patients were correctly clas-
sified as nonsurvivors, and 25 of 31 (80.7%) patients as sur-
vivors. Overall, 81% of the cases were correctly classified.
DISCUSSION
Diffuse infiltrates are usually a diagnostic challenge;
they are also the most severe pulmonary nosologic pattern
when compared to focal and nodular ones.13 At the timing
of writing, the role of surgical lung biopsies in the man-
agement of diffuse pulmonary infiltrates remains obscure.
Although such biopsies reveal some clinical homogeneity,
diffuse pulmonary infiltrates can originate from different
etiologies such as infectious pneumonias, organizing pneu-
monia, acute eosinophilic pneumonia, and pulmonary
capillaritis, which thus require different treatment strate-
gies.14
Several studies have been published concerning differ-
ent aspects of surgical lung biopsies in distinct populations
with diffuse infiltrates.15,16 Clinical implications of these
biopsies have been greatly exploited, mostly concerning
their contribution to the determination of prognosis through
therapeutic changes, but also because such surgical biopsied
can be carried out with relatively low morbidity and fre-
quently promote changes in treatment.17–20
Clearly, most of the studies concerning surgical lung
biopsies take into account only diagnostic information pro-
vided by routine histological analysis, usually regarded as
the gold standard for clinical hypotheses in diffuse infil-
trates,21 in addition to clinical data. Histopathological data
from surgical lung biopsies have rarely been exploited in
detail.22 The likely reason why such biopsies frequently fail
to provide information in routine use is that histopathologi-
cal details have not so far been adequately correlated with
either routine clinical or pathological analyses. Frequently,
clinical or radiological findings reflect such minimal tis-
sue changes that they can be result in misdiagnosis. The
question of interest is whether additional, more technologi-
cally enhanced information gathered from surgical lung bi-
opsies or from clinical records can help us to better pre-
dict a patient’s outcome. Lung pathology undoubtedly com-
prises a series of complex stereotyped reactions, which
make differential diagnosis using only qualitative ap-
proaches difficult. However, semiquantitative assessment is
thought to be useful because it facilitates the creation of
mathematical models to predict outcome. In a variety of
conditions, especially diffuse pulmonary parenchymal dis-
eases, a scoring system for quantitative assessment has been
associated with guidance or evaluation of therapy response
and prognosis.6–8 Thus, for all these reasons, we should not
be surprised to learn that detailed pulmonary analysis of
the different histological compartments, where alterations
are classified in accordance with their acute or chronic
character and semiquantified through a system of scores,
can provide a significant prognostic contribution.
In addition to presenting a scoring system, our purpose
included the correlation of histopathological findings of
data concerning survival and epidemiological parameters.
Descriptive analyses helped in selecting useful information
for which statistical significance was verified through mul-
tiple logistic regression.
Most of our diagnoses included airway diseases in the
same proportion as interstitial lung diseases; other studies
found a higher percentage of idiopathic pulmonary fibro-
sis.13,16,23–25
We found a negative influence of diffuse alveolar dam-
age and respiratory failure, mainly for men and with un-
derlying disease (P > 0.05). It is widely known that the
presence of underlying disease has a deleterious influence
on the outcome of a pneumopathy and that diffuse alveo-
lar damage is related to critical clinical pictures. Never-
theless, our study provided important quantitative informa-
tion concerning these parameters, showing a 17 fold in-
crease in risk of death in the presence of diffuse alveolar
damage. Perhaps, according to the objective of this study,
the most important evidence was the association of the
chronic histological changes with survival. In fact, a direct
association was found between low risk of dying and higher
values of chronic histological changes. Our results confirm
the prognostic importance of histopathological evaluation
of surgical lung biopsies. This is possibly the first study
concerning such biopsies with emphasis on detailed histo-
logical findings. Although further studies are required, our
results suggest that quantitative assessment accomplished
through a scoring system provides more prognostic infor-
mation than does the routine clinical and pathological ap-
proach.
In conclusion, the detailed histological analysis of sur-
gical lung biopsy specimens can provide more than noso-
logical diagnosis; this approach can bring valuable infor-
mation concerning prognosis. Additional study in a
randomized and prospective trial could confirm this con-
clusion. We also believe that it is important to validate our
semiquantitative assessment using a scoring system, as well
as to extend it to other histological types of diffuse pul-
monary disease, by studying the scoring system in addi-
tional patients.
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RESUMO
Canzian M, Soeiro A de M, Taga MF de L, Farhat C, Bar-
bas CSV, Capelozzi VL. Avaliação semiquantitativa da
biópsia pulmonar cirúrgica: valor preditivo e impacto na
sobrevida de pacientes com infiltrado pulmonar difuso.
Clinics. 2007;62(1):23-30.
PROPOSIÇÃO: A biópsia pulmonar cirúrgica tem sido
estudada em populações distintas, geralmente abordando
aspectos histopatológicos puramente diagnósticos em
infiltrados pulmonares difusos, além de dados clínicos.
Contudo, análises teciduais detalhadas em tais casos têm
sido pouco exploradas. O presente estudo foi delineado com
o intuito de se investigar a contribuição prognóstica
fornecida pela análise histológica detalhada em infiltrados
difusos.
MÉTODOS: Foram examinados retrospectivamente os
prontuários e biópsias pulmonares cirúrgicas de 63 paci-
entes maiores de 18 anos, com infiltrados difusos, de 1982
a 2003. O parênquima pulmonar foi dividido em 4 com-
partimentos histológicos: interstício, vias aéreas, vasos e
espaços alveolares. Alterações histológicas de cada com-
partimento histológico foram então avaliadas de acordo
com seu caráter evolutivo agudo ou crônico. Um escore
semiquantitativo foi aplicado a achados histopatológicos
com o intuito de se avaliar a intensidade e a extensão do
processo patológico. Aplicamos regressão logística para
predizer o risco de morte para alterações histológicas agu-
das e crônicas e para estimar a razão de probabilidades para
cada uma das variáveis independentes do modelo.
RESULTADOS: O impacto sobre a sobrevida foi obser-
vado para o gênero masculino (p=0.03), para a presença
de dano alveolar difuso (p=0.001) e para alterações
histológicas crônicas (p=0.0004) em biópsias. Assim, ho-
mens apresentariam menor chance (O.R. = 0.18; P=0.03)
de morrer do que mulheres. O risco de morte foi 17 vezes
maior na presença de alterações histológicas agudas como
dano alveolar difuso e 2,5 vezes na presença de alterações
histológicas crônicas.
CONCLUSÃO: A análise detalhada de espécimes
histológicos pode proporcionar maiores e mais valiosas in-
formações de valor prognóstico do que o simples diagnós-
tico nosológico.
UNITERMOS: Biópsia pulmonar cirúrgica. Infiltrado pul-
monar difuso. Escore histopatológico. Dano alveolar difuso.
Prognóstico.
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